NCT04656561.

Study name	A study investigating the efficacy and safety of intravitreal injections of ANX007 in patients with geographic atrophy (ARCHER)
Methods	Phase 2, controlled, randomised, double‐blind, parallel group study conducted at multiple centres
Participants	Adults 50 years and older with well‐demarcated GA due to AMD in at least one eye and BCVA of 24 to 83 letters on the ETDRS chart
Interventions	ANX007 administered every 4 weeks or every 8 weeks, compared to sham injection every 4 weeks or every 8 weeks
Outcomes	Primary outcome measure: Change in GA lesion area, as measured by FAF (time frame: 12 months) Secondary outcome measures: Number of participants with treatment‐emergent AEs (time frame: 18 months) Change in BCVA as assessed by ETDRS chart (time frame: 18 months) Change in LLVA (time frame: 18 months) Change in LLD (time frame: 18 months)
Starting date	December 2020
Contact information	Annexon, Inc.
Status	Active, not recruiting
Required reporting date	June 2024
Notes	—